Javascript is disabled

Javascript seems to be disabled. This will break some core site features. Please enable javascript or revisit this site from another device.



Platinum sponsor

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at

Gold sponsors

aTyr Pharma is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its tRNA synthetase platform. aTyr’s lead therapeutic candidate, efzofitimod, is a selective modulator of neuropilin-2 that downregulates innate immune responses in uncontrolled inflammatory disease states. aTyr is developing efzofitimod as a potential disease-modifying therapy to resolve chronic inflammation and prevent the progression of fibrosis in forms of interstitial lung disease. aTyr is currently conducting EFZO-FIT™, a global pivotal Phase 3 study of efzofitimod in pulmonary sarcoidosis, and is planning to initiate a Phase 2 study in SSc-ILD in 2023.

Established in 2020, Xentria works across biopharmaceutics communities creating innovative and authentic collaborations and partnerships that advance challenging drug development. Xentria, derived from “centrality”, is dedicated to delivering customized approaches to ambitious drug innovation through meaningful patient engagement and effective partnerships. Headquartered in Chicago, Xentria is taking the lead to support surging life sciences initiatives for global audiences, while nurturing diversity, individualism, and sustainability. Xentria is developing XTMAB-16, an anti-TNFα monoclonal antibody which will be tested in a clinical trial for its ability to reduce an inflammatory response believed to occur in patients having pulmonary sarcoidosis, a chronic, multisystem inflammatory disorder. XTMAB-16 could emerge as one of a few therapeutics specifically developed for and indicated for treatment of pulmonary sarcoidosis in contrast to symptomatic steroid treatment as the current standard of care.
To learn more about Xentria visit

Silver sponsor